-
High-throughput screening uses robots to test the actions of thousands of compounds against a molecular disease target (itself identified by genomics).
FORBES: A hail of silver bullets
-
Scientists probing the molecular origins of heart disease are discovering surprising parallels between these two kinds of disorders, paving the way for new treatments.
FORBES: Prevention Puzzle
-
The MRC-NIHR Phenome Centre will look for new molecular 'biomarkers' for disease by analysing samples from patients and volunteers.
BBC: Legacy for anti-doping centre
-
Into this gloom comes Novartis' Glivec, the first leukemia drug designed to attack the molecular machinery that drives the disease.
FORBES: The Race for a Cure
-
SU-11248 is one of a new spate of cancer pills that work by targeting several of the molecular defects that cause the disease at one time.
FORBES: Pfizer Cancer Pill Proves Effective
-
"My vision is that we will have drugs targeting key elements of molecular pathways" that go awry in disease, Fishman says.
FORBES: Magazine Article
-
By 2000, scientists had identified nearly 40 other genes involved in the disease, as well as various other molecular changes that cause muscles to waste away.
WSJ: New Muscular Dystrophy Drugs Offer Hope
-
"The disease is common, but the fatalities are the puzzle we're trying to figure out, " says Dr. Jim Alexander, a molecular virologist with the Atlanta-based Centers for Disease Control and Prevention.
CNN: Why Are the Infants Dying?
-
When Schleifer, a 50-year-old neurologist, cofounded Regeneron with George Yancopoulos , a molecular immunologist, the main target was Lou Gehrig's disease.
FORBES: Hunger Pangs
-
The University of Colorado researchers are studying molecular mechanisms of normal acclimatization in healthy people to gain new treatment ideas for people with chronic obstructive pulmonary disease, or COPD, a common lung disease.
WSJ: Mayo Clinic Researchers on Everest Study High Altitude's Effects on the Body
-
"Obesity is a disease that is crippling the healthcare system, " says Stephen Friend , Merck's vice president of molecular profiling.
FORBES: Magazine Article